Ceftizoxime |
Catalog No.GC32229 |
세프티족심은 세균의 세포벽 합성을 방해하고 펩티도글리칸의 가교를 억제함으로써 작용하는 세균 억제제입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 68401-81-0
Sample solution is provided at 25 µL, 10mM.
Ceftizoxime is a bacterial inhibitor which acts by interfering with bacterial cell wall synthesis and inhibiting cross-linking of the peptidoglycan.
Ceftizoxime is a new parenteral cephalosporin derivative which is more active against various gram-negative bacilli, including the opportunistic pathogens such as Enterobacter, Citrobacter species, and Serratia marcescens, than cephalosporins and cephamycins such as cefotiam, cefamandole, cefuroxime, cefotaxime, and cefmetazole. Ceftizoxime shows a broad spectrum of antibacterial activity against aerobic gram-positive and gram-negative bacteria[1].
The therapeutic effect of Ceftizoxime in mice infected with a small inoculum size is almost the same as that of cefotaxime[1]. Ceftizoxime is stable in biological fluids such as serum, urine, and tissue homogenates, but cefotaxime is unstable in rat tissue homogenates. Binding of ceftizoxime to serum protein in all species is the lowest of all the antibiotics: 31% for humans, 17% for dogs, and 32% for rats[2].
[1]. Kamimura T, et al. Ceftizoxime (Ceftizoxime), a new parenteral cephalosporin: in vitro and in vivo antibacterial activities. Antimicrob Agents Chemother. 1979 Nov;16(5):540-8. [2]. Murakawa T, et al. Pharmacokinetics of ceftizoxime in animals after parenteral dosing. Antimicrob Agents Chemother. 1980 Feb;17(2):157-64.
Average Rating: 5
(Based on Reviews and 23 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *